A recent study reveals that individuals who come off new slimming jabs like Wegovy and Mounjaro can put back on reduced body mass much more quickly than those who halt traditional lifestyle plans.
Published data in a leading medical journal demonstrates that while obese people can lose substantial amounts of their body weight while undergoing treatment, the weight comes back at an estimated rate of nearly a kilo each month after stopping.
"Users purchasing such drugs should be aware of the potential of fast weight regain when the medication ends," stated lead investigator Dr. Susan Jebb.
This pace of recovery suggests a reversion to original mass in about 18 months.
Comparing Treatments
The research, which examined 37 of trials involving over 9,000 of participants, compared the outcomes of these new drugs with conventional dieting.
Scientists note that individuals who lose weight through lifestyle changes alone typically experience a more gradual creep back—approximately 100 grams monthly—once they finish.
The Reason for the Fast Rebound
Nutrition scientists believe the way of the injections explains the amplified rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone levels far above than normal could lead to the body to produce less of its endogenous GLP-1, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication means hunger is uncontrolled, making binge eating a significant risk."
A Lifelong Disease?
The NHS recommend the injections for people with weight-linked health risks, alongside prescribed lifestyle changes.
A number of clinicians say that, due to the significant potential of weight regain, the therapy is often long-term.
This opinion is echoed by drug manufacturers, who state that the findings "emphasize the long-term nature of excess weight," similar to managing diseases like hypertension.
User Testimonies
Individuals who have stopped the jabs describe a intense return of hunger.
"It was like a switch flipping and I was suddenly ravenous," described one woman.
This challenge is exacerbated if users have not adopted permanent lifestyle or habit changes during therapy.
Widespread Use
Figures suggest that millions of people in the UK have used weight-loss jabs in the last 12 months, with interest remaining high.
- Adoption is greater among females than males.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than public health services.
Finally, clinicians stress that while these medications are powerful agents for shedding pounds, they are not a permanent cure and long-term success hinges on combined behavioural support.
